Derivation Web

source_5dfa66abfeba4f96

by researka:v2 · 2026-06-18 16:12:34.645762+04:00

# Research Synthesis: NAD+ Metabolism Effects — full paper

## Abstract

Evidence-honesty note: 8/12 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

This paper synthesizes evidence on NAD+ metabolism effects across 12 included source papers and 804 high-confidence extracted claims.

The evidence profile contains no sources classified primarily as direct interventional hard-endpoint evidence, 12 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 0 cross-study disagreements across the evidence base.

No single positive outcome class dominates the retained corpus; null signals cluster in the contextual adjacent evidence, cardiometabolic, safety and comorbidity outcome classes, and negative signals cluster in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that NAD+ metabolism effects should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.

## Methods

### Review type and protocol
This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-nad_metabolism_effects-v06-DAILY-2026-06-18T12-02-31Z`.

### Information sources
Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-18.

### Search strategy
The following topic-anchored queries were executed against the information sources listed above:

- `nad metabolism effects aging`
- `nad metabolism effects older adults`
- `nad metabolism effects randomized controlled trial`
- `nad aging`
- `nad older adults`
- `nad randomized controlled trial`
- `metabolism aging`
- `metabolism older adults`
- `metabolism randomized controlled trial`
- `nicotinamide riboside aging`

### Eligibility criteria
- Sources whose primary content addresses nad metabolism effects.
- Sources with extractable quantitative or qualitative findings.
- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

### Selection of sources of evidence
The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 175 records in the receipt-candidate union, 55 were classified as source candidates and 12 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

### source admission funnel

| Admission bucket | n |
|---|---:|
| Receipt candidate union | 175 |
| Classified source candidates | 55 |
| No extractable claims | 34 |
| None-only claim binding | 13 |
| Mixed partial-or-none claim-binding candidates | 47 |
| Partial-only claim-binding candidates | 14 |
| Strict high-confidence sources | 12 |
| Admitted final sources | 12 |

### Exclusion reasons
- No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.

### Data items
The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.

### Risk-of-bias appraisal
Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses).

### Synthesis approach
Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, frailty, muscle function, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

### AI-use disclosure
Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

### Accountability
Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

## Results

**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.


| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |
|---|---|---|---|---|
| Contextual Adjacent Evidence | n=5; claims=146 | no extracted directional signal in 5/5 sources | 3 indirect; 2 review | limited corpus depth in this outcome class |
| Cardiometabolic | n=3; claims=306 | unclear signal in 2/3 sources | 2 indirect; 1 review | limited corpus depth in this outcome class |
| Muscle Function | n=2; claims=202 | unclear signal in 2/2 sources | 2 indirect | limited corpus depth in this outcome class |
| Frailty | n=1; claims=13 | no extracted directional signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |
| Safety and Comorbidity | n=1; claims=137 | no extracted directional signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating |

This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.

### Contextual Adjacent Evidence Outcomes

5 included sources were assigned to this outcome class. Directional coding: null=5. Directness coding: indirect=3, review=2.

### Cardiometabolic Outcomes

3 included sources were assigned to this outcome class. Directional coding: null=1, unclear=2. Directness coding: indirect=2, review=1.

### Muscle Function Outcomes

2 included sources were assigned to this outcome class. Directional coding: unclear=2. Directness coding: indirect=2.

### Frailty Outcomes

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.

### Safety Comorbidity Outcomes

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: review=1.

## Limitations

**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.


The most consequential scope limitation is the absence of long-term, hard-outcome trials of NAD+-precursor supplementation in the curated corpus. As a result, the human evidence base for NAD+ is restricted to short-horizon pharmacodynamic and biomarker readouts, and the inferred clinical benefit is anchored to mechanistic extrapolation rather than to trial-level demonstration of event reduction. The Ioannidis 2005 caution that surrogate associations do not guarantee hard-outcome validity applies directly: every quantitative efficacy statement in this synthesis is a surrogate-endpoint claim, and the bridge to clinical events is unsupported within the corpus.

Several clinically relevant outcomes are touched by only a single source, so the within-corpus replication requirement cannot be met. Likewise, Holmes 2026 is the sole source addressing menopausal-symptom frequency and severity, and Gao 2026 is the sole source examining NAD+ biology in an acute respiratory distress syndrome context (P < 0.0001 for the SERPINE1–Sirt3 axis). Conclusions drawn from these single-source outcomes cannot be triangulated against an independent trial in the corpus and should therefore be read as hypothesis-generating rather than as replicated findings.

Population specificity constrains external validity. Women, younger adults, and patients with established cardiometabolic disease, chronic kidney disease, or hepatic impairment are largely absent, so the within-corpus generalisation is restricted to relatively healthy, predominantly male, older Western and East Asian cohorts.

Endpoint scope within the available trials is narrow. Because the EWGSOP2 sarcopenia cutoffs (27 kg for men, 16 kg for women, per Cruz-Jentoft 2019) and gait-speed thresholds (0.8 m/s, Studenski 2011; 0.6 m/s, Cesari 2009) are not directly applied as enrolment or outcome definitions in the available trials, the corpus cannot adjudicate whether NAD+-precursor supplementation shifts participants across these clinically meaningful functional boundaries.

Finally, a mechanism-to-clinic gap is visible for the cognitive endpoint. The Qader 2025 systematic review of NAD+ precursors in cognitive disease is restricted to rodent models, leaving the human cognitive claim under-supported mechanistically by Qader 2025 and confounded clinically by Yulug 2023. Without a monotherapy RCT in a defined cognitive-impaired population, the cognitive arm of the NAD+ case rests on indirect preclinical evidence supplemented by a multi-component clinical signal that cannot be attributed to NAD+-precursor exposure specifically.

## Conclusion

For NAD+ metabolism effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

## What This Synthesis Adds

This synthesis maps 12 included sources on NAD+ Metabolism Effects across 5 outcome classes with no cross-study disagreements surfaced. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

Across 12 curated reference papers, the evidence base for NAD+ shows a context-dependent profile. Null findings dominate: contextual other, cardiometabolic. The NAD+ anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.

In animal/preclinical evidence, prior reviews in the corpus (Chen 2024) emphasize convergent signals on NAD+ Metabolism Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

### Boundary-Condition Matrix

| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |
|---|---:|---:|---|---|
| cardiometabolic | 0 | 3 | null, unclear | direct interventional hard-endpoint gap |
| frailty | 0 | 1 | null | direct interventional hard-endpoint gap |
| muscle function | 0 | 2 | unclear | direct interventional hard-endpoint gap |
| contextual adjacent evidence | 0 | 5 | null | direct interventional hard-endpoint gap |
| safety and comorbidity | 0 | 1 | null | direct interventional hard-endpoint gap |

### Evidence-Gap Priority

| Priority | Gap | Rationale |
|---|---|---|
| P1 | cardiometabolic: direct interventional hard-endpoint gap | 0 direct and 3 indirect sources; direction profile: null, unclear |
| P2 | frailty: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null |
| P3 | muscle function: direct interventional hard-endpoint gap | 0 direct and 2 indirect sources; direction profile: unclear |
| P4 | contextual adjacent evidence: direct interventional hard-endpoint gap | 0 direct and 5 indirect sources; direction profile: null |
| P5 | safety and comorbidity: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null |

### Next-Study Design Recommendation

The next high-yield study for NAD+ Metabolism Effects should target the **cardiometabolic** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

## Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

### Load-Bearing Included Studies

- Additional corpus sources included animal/preclinical evidence; Chen 2024; tier=B1; directness=review; endpoint=cardiometabolic; direction=unclear; representative statistic=P = 0.06.
- Katayoshi 2023; tier=B2; directness=indirect; endpoint=cardiometabolic; direction=null; representative statistic=P = 0.097.
- Connell 2021; tier=B2; directness=indirect; endpoint=muscle function; direction=unclear; representative statistic=P = 0.001.
- Conze 2019; tier=B2; directness=review; endpoint=safety comorbidity; direction=null; representative statistic=p ≤ 0.05.
- Martens 2018; tier=B2; directness=indirect; endpoint=cardiometabolic; direction=unclear; representative statistic=P < 0.006.
- Yulug 2023; tier=B2; directness=review; endpoint=contextual adjacent evidence; direction=null; representative statistic=P > 0.05.
- Elhassan 2019; tier=B2; directness=indirect; endpoint=muscle function; direction=unclear; representative statistic=P < 0.001.
- Qader 2025; tier=B2; directness=review; endpoint=contextual adjacent evidence; direction=null.
- Holmes 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null.
- Christen 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null.

### Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

- Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=32.
- Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=177.
- NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults: outcome=muscle function; directness=indirect; tier=B2; direction=unclear; claims=148.
- Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults: outcome=safety comorbidity; directness=review; tier=B2; direction=null; claims=137.
- Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD + in healthy middle-aged and older adults: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=97.
- Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=69.
- Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD + Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures: outcome=muscle function; directness=indirect; tier=B2; direction=unclear; claims=54.
- A systematic review of the therapeutic potential of nicotinamide adenine dinucleotide precursors for cognitive diseases in preclinical rodent models: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=34.
- Nicotinamide riboside and pterostilbene reduces frequency and severity of undesirable symptoms of the menopause transition: an open-label, pilot clinical trial: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=19.
- The differential impact of three different NAD + boosters on circulatory NAD and microbial metabolism in humans: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=17.
- Trigonelline is an NAD + precursor that improves muscle function during ageing and is reduced in human sarcopenia: outcome=frailty; directness=indirect; tier=B2; direction=null; claims=13.
- SERPINE1 drives ferroptosis in acute respiratory distress syndrome by disrupting mitochondrial NAD + homeostasis and suppressing Sirt3 activity: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=7.

### Classification Criteria

- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

### Load-Bearing Tensions

- No load-bearing cross-study disagreements were detected.



Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Membrez 2024, Bohannon 1997.

## References

- **Katayoshi 2023.** _Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial._ Scientific Reports, 2023. DOI: 10.1038/s41598-023-29787-3. PMID: 36797393.
- **Connell 2021.** _NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults._ The Journal of Nutrition, 2021. DOI: 10.1093/jn/nxab193. PMID: 34191033.
- **Conze 2019.** _Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults._ Scientific Reports, 2019. DOI: 10.1038/s41598-019-46120-z. PMID: 31278280.
- **Martens 2018.** _Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD + in healthy middle-aged and older adults._ Nature Communications, 2018. DOI: 10.1038/s41467-018-03421-7. PMID: 29599478.
- **Yulug 2023.** _Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial._ Translational Neurodegeneration, 2023. DOI: 10.1186/s40035-023-00336-2. PMID: 36703196.
- **Elhassan 2019.** _Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD + Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures._ Cell Reports, 2019. DOI: 10.1016/j.celrep.2019.07.043. PMID: 31412242.
- **Qader 2025.** _A systematic review of the therapeutic potential of nicotinamide adenine dinucleotide precursors for cognitive diseases in preclinical rodent models._ BMC Neuroscience, 2025. DOI: 10.1186/s12868-025-00937-9. PMID: 40033213.
- **Chen 2024.** _Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials._ Current Diabetes Reports, 2024. DOI: 10.1007/s11892-024-01557-z. PMID: 39531138.
- **Holmes 2026.** _Nicotinamide riboside and pterostilbene reduces frequency and severity of undesirable symptoms of the menopause transition: an open-label, pilot clinical trial._ Frontiers in Aging, 2026. DOI: 10.3389/fragi.2026.1773667. PMID: 42211736.
- **Christen 2026.** _The differential impact of three different NAD + boosters on circulatory NAD and microbial metabolism in humans._ Nature Metabolism, 2026. DOI: 10.1038/s42255-025-01421-8. PMID: 41540253.
- **Membrez 2024.** _Trigonelline is an NAD + precursor that improves muscle function during ageing and is reduced in human sarcopenia._ Nature Metabolism, 2024. DOI: 10.1038/s42255-024-00997-x. PMID: 38504132.
- **Gao 2026.** _SERPINE1 drives ferroptosis in acute respiratory distress syndrome by disrupting mitochondrial NAD + homeostasis and suppressing Sirt3 activity._ Redox Biology, 2026. DOI: 10.1016/j.redox.2026.104146. PMID: 42190562.

### Background References

*Canonical reference values and methodological references cited in prose. Each entry's `citation_token` appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).*

- **Studenski 2011.** _Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-58._ DOI: 10.1001/jama.2010.1923. PMID: 21205966.
- **Cesari 2009.** _Cesari M, Kritchevsky SB, Newman AB, et al. Added value of physical performance measures in predicting adverse health-related events. J Gerontol A Biol Sci Med Sci. 2009;64(7):772-779._ DOI: 10.1093/gerona/glp012. PMID: 19349594.
- **Bohannon 1997.** _Bohannon RW. Comfortable and maximum walking speed of adults aged 20-79 years: reference values and determinants. Age Ageing. 1997;26(1):15-19._ DOI: 10.1093/ageing/26.1.15.
- **Cruz-Jentoft 2019.** _Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31._ DOI: 10.1093/ageing/afy169. PMID: 30312372.
- **Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ (methodological reference) DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.

{
  "article_type": "evidence_map",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "edd58f8b-265b-4476-81cd-a6dde044e4dc",
  "title": "Research Synthesis: NAD+ Metabolism Effects \u2014 full paper"
}